{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:00:03Z","timestamp":1787497203610,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The projects of of Chengdu Science and Technology Bureau","award":["2015-HM01-00482-SF"],"award-info":[{"award-number":["2015-HM01-00482-SF"]}]},{"name":"The project of health commission of Sichuan province","award":["19PJ003"],"award-info":[{"award-number":["19PJ003"]}]},{"name":"The project of Sichuan Science and Technology Bureau","award":["2017SZ0142"],"award-info":[{"award-number":["2017SZ0142"]}]},{"name":"The project of Sichuan Science and Technology Bureau","award":["2020YFS0490"],"award-info":[{"award-number":["2020YFS0490"]}]},{"name":"National Key R&D Program of China","award":["2018YFA0108604"],"award-info":[{"award-number":["2018YFA0108604"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events and diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events in statin-intolerant patients with hypercholesterolemia. The primary outcomes were major adverse cardiac events, and percent change in LDL-C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 11 trials including a total of 4391 participants. Bempedoic acid use was associated with a reduction in composite cardiovascular outcome (RR 0.75, 95% CI 0.56\u20130.99; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). Bempedoic acid reduced LDL-C levels (MD \u2212\u00a022.91, 95% CI \u2212\u00a027.35 to \u2212\u00a018.47; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999%), and similarly reduced CRP levels (MD -24.70, 95% CI \u2212\u00a032.10 to \u2212\u00a017.30; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200953%). Bempedoic acid was associated with a reduction in rates of new-onset or worsening diabetes (RR 0.65, 95% CI 0.44\u20130.96; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200923%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascular events and diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-020-01101-9","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T11:04:08Z","timestamp":1597230248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Xing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weelic","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-1920","authenticated-orcid":false,"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"issue":"12","key":"1101_CR1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013e492.","journal-title":"Circulation"},{"issue":"17","key":"1101_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"24","key":"1101_CR3","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1016\/j.jacc.2018.11.004","volume":"73","author":"PWF Wilson","year":"2019","unstructured":"Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3210\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"1101_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319845314","author":"CR Sirtori","year":"2019","unstructured":"Sirtori CR, Yamashita S, Greco MF, Corsini A, Watts GF, Ruscica M. Recent advances in synthetic pharmacotherapies for dyslipidaemias. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319845314.","journal-title":"Eur J Prev Cardiol"},{"key":"1101_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319864671","author":"CM Ballantyne","year":"2019","unstructured":"Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319864671.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"1101_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","volume":"13","author":"ND Lalwani","year":"2019","unstructured":"Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13(4):568\u201379.","journal-title":"J Clin Lipidol"},{"issue":"18","key":"1101_CR7","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"12","key":"1101_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","volume":"117","author":"CM Ballantyne","year":"2016","unstructured":"Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, Lalwani ND. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117(12):1928\u201333.","journal-title":"Am J Cardiol"},{"issue":"13","key":"1101_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"1101_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"7","key":"1101_CR11","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1101_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"1101_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, Trial CH. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"1101_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556\u201367.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1101_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295\u2013304.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1101_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccl.2017.12.007","volume":"36","author":"A Saeed","year":"2018","unstructured":"Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36(2):257\u201364.","journal-title":"Cardiol Clin"},{"issue":"2","key":"1101_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5603\/KP.a2019.0013","volume":"77","author":"X Wang","year":"2019","unstructured":"Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019;77(2):207\u201316.","journal-title":"Kardiol Pol"},{"issue":"290","key":"1101_CR18","first-page":"140","volume":"2019","author":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies","year":"2019","unstructured":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;2019(290):140\u2013205.","journal-title":"Atherosclerosis"},{"key":"1101_CR19","unstructured":"New Lipid-Lowering Drug Earns FDA Approval. 2020. https:\/\/www.medscape.com\/viewarticle\/925580. Accessed 1 Jul 2020."},{"key":"1101_CR20","unstructured":"EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe. 2020. https:\/\/www.medscape.com\/viewarticle\/924631. Accessed 1 Jul 2020."},{"issue":"4","key":"1101_CR21","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65\u201394.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1101_CR22","first-page":"154","volume":"35","author":"A Shinichi","year":"2014","unstructured":"Shinichi A. Cochrane handbook for systematic reviews of interventions. Online Kensaku. 2014;35(3):154\u20135.","journal-title":"Online Kensaku"},{"issue":"7650","key":"1101_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"11","key":"1101_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7109","key":"1101_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"13","key":"1101_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, MacDougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1101_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, Macdougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295\u2013304.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1101_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556\u201367.","journal-title":"J Clin Lipidol"},{"issue":"18","key":"1101_CR29","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Barton Duell P. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1101_CR30","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1101_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"1101_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MOL.0000000000000091","volume":"25","author":"S Filippov","year":"2014","unstructured":"Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014;25(4):309\u201315.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"1101_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"issue":"18","key":"1101_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2019.16598","volume":"322","author":"MC Honigberg","year":"2019","unstructured":"Honigberg MC, Natarajan P. Bempedoic acid for lowering LDL cholesterol. JAMA. 2019;322(18):1769\u201371.","journal-title":"JAMA"},{"issue":"7","key":"1101_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","volume":"20","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20(7):791\u2013803.","journal-title":"Expert Opin Pharmacother"},{"key":"1101_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00399-w","author":"S Niman","year":"2020","unstructured":"Niman S, Rana K, Reid J, Sheikh-Ali M, Lewis T, Choksi RR, Goldfaden RF. A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia. Am J Cardiovasc Drugs. 2020. https:\/\/doi.org\/10.1007\/s40256-020-00399-w.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"1101_CR37","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/imj.14291","volume":"49","author":"YM Cheung","year":"2019","unstructured":"Cheung YM, O'Brien R, Ekinci EI. What is new in lipid-lowering therapies in diabetes? Intern Med J. 2019;49(12):1472\u201380.","journal-title":"Intern Med J"},{"issue":"4","key":"1101_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pcad.2019.07.006","volume":"62","author":"M Gupta","year":"2019","unstructured":"Gupta M, Tummala R, Ghosh RK, Blumenthal C, Philip K, Bandyopadhyay D, Ventura H, Deedwania P. An update on pharmacotherapies in diabetic dyslipidemia. Prog Cardiovasc Dis. 2019;62(4):334\u201341.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"1101_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-019-0951-9","volume":"18","author":"KK Ray","year":"2019","unstructured":"Ray KK, Del Prato S, Muller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, et al. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol. 2019;18(1):149.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1101_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-019-0949-3","volume":"18","author":"C Caselli","year":"2019","unstructured":"Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, Scholte A, De Caterina R, Neglia D. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019;18(1):144.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1101_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-018-0740-x","volume":"17","author":"LL O'Mahoney","year":"2018","unstructured":"O'Mahoney LL, Matu J, Price OJ, Birch KM, Ajjan RA, Farrar D, Tapp R, West DJ, Deighton K, Campbell MD. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1101_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-019-0887-0","volume":"18","author":"O Sheikh","year":"2019","unstructured":"Sheikh O, Vande Hei AG, Battisha A, Hammad T, Pham S, Chilton R. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019;18(1):84.","journal-title":"Cardiovasc Diabetol"},{"key":"1101_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2017.00363","volume":"8","author":"C Peir\u00f3","year":"2017","unstructured":"Peir\u00f3 C, Lorenzo \u00d3, Carraro R, S\u00e1nchez-Ferrer CF. IL-1\u03b2 inhibition in cardiovascular complications associated to diabetes mellitus. Front Pharmacol. 2017;8:363.","journal-title":"Front Pharmacol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01101-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T19:39:13Z","timestamp":1628710753000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01101-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01101-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}